Skip to main content
. 2021 Aug 22;71(4):829–838. doi: 10.1007/s00262-021-03035-x

Fig. 3.

Fig. 3

Survival outcomes according to changes in NK cell activity among patients with NK cell activity data after two cycles of treatment (n = 38). A, B Progression-free survival (PFS) and overall survival (OS) in the high baseline, recovered, and persistently low NK groups. C, D PFS and OS in the high baseline or recovered NK group and the persistently low NK group among patients with moderate to poor risk (n = 26)